A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-Week Dose-Response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes.
Phase of Trial: Phase II/III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Rivoglitazone (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 31 Aug 2018 Biomarkers information updated
- 06 Apr 2010 Results published in Current Medical Research and Opinion.
- 10 Sep 2007 Status changed from in progress to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History